Other features that correlate with IDH mutation status include normal karyotype, intermediate-risk cytogenetics, NPM1 mutation, and M1 AML subtype (Chou et al., 2010; Schnittger et al., 2010).
The most strongly differentially enriched pathways between breast cancers stratified by TP53 mutation status include in addition to TP53 signalling, several known cancer pathways involved in renal, prostate, pancreatic, colorectal, lung and other cancers, and signalling pathways such as calcium signalling, MAPK, ERBB and vascular endothelial growth factor (VEGF) signalling pathways.
We assessed the effect of niraparib on HGSOC patient-derived xenograft (PDX) models as well as the relationship between certain markers of homologous recombination (HR) status, including BRCA1/2 mutations and formation of RAD51 foci after DNA damage, and response of these PDXs to niraparib in vivo.
The results suggest that EGFR protein expression may predict EGFR gene status (including copy number and mutation) to some extent.
For the replication of the association found when patients were stratified according to the RET mutation status, we included 21 independent HSCR cases bearing RET CDS mutations and 71 control individuals from Mainland China (replication group).
The cohort was examined with respect to mutation status, clinicopathological parameters including TNM staging, grade, histological subtype and intrinsic phenotype.
In a recent whole-exome sequencing analysis of 99 pancreatic cancer specimens, the top 16 most frequently mutated genes were identified, including KRAS and TP53, but the FBW7 gene mutation status was not included.
Although the assessment of K-ras mutation status has been included in clinical guidelines for patients with CRC, a significant fraction of patients with wild-type K-ras fail to respond to cetuximab (http://www.cancer.gov/cancertopics/druginfo/fda-cetuximab).
The EGFR mutation status was not included as a variable in the analysis, and the test population was small, consisting of only 50 patients.
Again, we were restricted to patients tested for EGFR mutation status, but could include trials that exclusively recruited patients with wild type EGFR.
